Ted Danson's new show will feature AI effort to treat disease

Danielle Brown | | Health Exec | Precision Medicine

A television series led by actor Ted Danson will showcase how a company is using various technologies, including AI, to help treat type 2 diabetes in India.

"The Advancements with Ted Danson" television series is planning to feature genomics and precision medicine company Shivom in an upcoming episode. The company is using its data and technology—like genomics, blockchain and AI—to help improve the diagnosis and treatment of type 2 diabetes in India. Type 2 diabetes affects about 72 million people in India, and incidences have quadrupled in the last 35 years, according to Shivom.

“The process will involve collecting saliva samples of the patients from which DNA will be extracted, analyzed and secured on Shivom’s blockchain-based genomics datahub. Shivom’s partner—diagnostics leader Genetic Technologies Limited—will help analyze the collected anonymous genomic-samples and data with the goal of developing a diagnostic SNP panel specific to the Indian population,” the company said in a press release.

The show will air at 3:30 p.m. ET on Sunday, Dec. 16 on CNBC.

""
Danielle Brown

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.